Acceleron Pharma Inc Expected to Earn Q1 2018 Earnings of ($0.62) Per Share (XLRN)
Acceleron Pharma Inc (NASDAQ:XLRN) – Analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for shares of Acceleron Pharma in a research report issued to clients and investors on Wednesday. Leerink Swann analyst G. Porges anticipates that the biopharmaceutical company will earn ($0.62) per share for the quarter.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). The company had revenue of $3.71 million for the quarter, compared to analysts’ expectations of $3.39 million. Acceleron Pharma had a negative net margin of 804.49% and a negative return on equity of 38.71%.
Acceleron Pharma (XLRN) opened at $41.91 on Friday. The stock has a market capitalization of $1,960.00, a P/E ratio of -15.58 and a beta of 1.39. Acceleron Pharma has a 1 year low of $24.37 and a 1 year high of $46.93.
Several institutional investors and hedge funds have recently modified their holdings of XLRN. New York State Common Retirement Fund raised its stake in shares of Acceleron Pharma by 11.7% in the second quarter. New York State Common Retirement Fund now owns 34,300 shares of the biopharmaceutical company’s stock valued at $1,042,000 after buying an additional 3,599 shares during the period. Northern Trust Corp raised its stake in shares of Acceleron Pharma by 13.0% in the second quarter. Northern Trust Corp now owns 381,370 shares of the biopharmaceutical company’s stock valued at $11,589,000 after buying an additional 43,891 shares during the period. Vanguard Group Inc. raised its stake in shares of Acceleron Pharma by 6.1% in the second quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after buying an additional 116,705 shares during the period. Parametric Portfolio Associates LLC raised its stake in shares of Acceleron Pharma by 3.9% in the second quarter. Parametric Portfolio Associates LLC now owns 9,456 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 355 shares during the period. Finally, Voya Investment Management LLC raised its stake in shares of Acceleron Pharma by 26.2% in the second quarter. Voya Investment Management LLC now owns 14,620 shares of the biopharmaceutical company’s stock valued at $444,000 after buying an additional 3,038 shares during the period. Hedge funds and other institutional investors own 90.13% of the company’s stock.
In other Acceleron Pharma news, SVP Christopher Rovaldi sold 2,266 shares of the business’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $42.42, for a total value of $96,123.72. Following the sale, the senior vice president now directly owns 52,977 shares in the company, valued at $2,247,284.34. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jean George sold 105,122 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the sale, the director now owns 1,250 shares in the company, valued at $44,662.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 146,021 shares of company stock worth $5,529,598. Corporate insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Acceleron Pharma Inc Expected to Earn Q1 2018 Earnings of ($0.62) Per Share (XLRN)” was posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this story can be read at https://www.dailypolitical.com/2018/03/03/acceleron-pharma-inc-expected-to-earn-q1-2018-earnings-of-0-62-per-share-xlrn.html.
Acceleron Pharma Company Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.